» Articles » PMID: 24433541

STMN-1 is a Potential Marker of Lymph Node Metastasis in Distal Esophageal Adenocarcinomas and Silencing Its Expression Can Reverse Malignant Phenotype of Tumor Cells

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2014 Jan 18
PMID 24433541
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Distal esophageal adenocarcinoma is a highly aggressive neoplasm. Despite advances in diagnosis and therapy, the prognosis is still poor. Stathmin (STMN-1) is a ubiquitously expressed microtubule destabilizing phosphoprotein. It promotes the disassembly of microtubules and prevents assembly. STMN-1 can cause uncontrolled cell proliferation when mutated and not functioning properly. Recently, found to be overexpressed in many types of human cancers. However, its clinical significance remains elusive in distal esophageal adenocarcinoma. Here, we reported for the first time that STMN-1 is highly overexpressed in adenocarcinomas of the distal esophagus and strongly associated with lymph node metastasis.

Methods: STMN-1 expression in 63 cases of distal esophageal adenocarcinoma was analyzed by immunoblotting, while expression in esophageal adenocarcinoma cells was determined by immunocytochemistry, immunofluorescence, qRT-PCR and western blotting. Lentivirus-mediated RNAi was employed to knock-down STMN-1 expression in Human esophageal adenocarcinoma cells. The relationship between STMN-1 expression and lymph node metastasis in distal esophageal adenocarcinoma was determined by univariate and multivariate analyses.

Results: STMN-1 was detected in 31 (49.21%) of the 63 cases. STMN-1 was highly overexpressed in specimens with lymph node metastasis pN (+), but its expression was almost undetected in pN (-) status. Multivarian regression analysis demonstrated that STMN-1 overexpression is an independent factor for lymph node metastasis in distal esophageal adenocarcinoma. STMN-1 shRNA effectively reduced STMN-1 expression in esophageal adenocarcinoma cells (P < 0.05), which significantly suppressed proliferation (P < 0.05), increased migration (P < 0.05) and invasion ability (P < 0.05) and G1 phase arrest (P < 0.05) which lead to induction of apoptosis in esophageal adenocarcinoma cells in vitro. To verify the in vitro data, we conducted in vivo tumor xenograft studies. Esophageal adenocarcinoma cells stably transfected with STMN-1 shRNA significantly reduced tumor xenografts volume in vivo.

Conclusions: STMN-1 overexpression is associated with lymph node metastasis and increase malignancy in distal esophageal adenocarcinoma. In vivo and in vitro laboratory findings, suggests that STMN-1 may be a suitable target for future therapeutic strategies in distal esophageal adenocarcinoma.

Citing Articles

A glycolysis-related gene signature predicts prognosis of patients with esophageal adenocarcinoma.

Kang H, Wang N, Wang X, Zhang Y, Lin S, Mao G Aging (Albany NY). 2020; 12(24):25828-25844.

PMID: 33234735 PMC: 7803571. DOI: 10.18632/aging.104206.


Zyxin (ZYX) promotes invasion and acts as a biomarker for aggressive phenotypes of human glioblastoma multiforme.

Wen X, Luo T, Jiang Y, Wang L, Luo Y, Chen Q Lab Invest. 2020; 100(6):812-823.

PMID: 31949244 DOI: 10.1038/s41374-019-0368-9.


High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Reyes H, Miecznikowski J, Gonzalez-Bosquet J, Devor E, Zhang Y, Thiel K Gynecol Oncol. 2017; 146(2):247-253.

PMID: 28532857 PMC: 5526627. DOI: 10.1016/j.ygyno.2017.05.017.


High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.

Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M Br J Cancer. 2017; 116(9):1177-1185.

PMID: 28334732 PMC: 5418450. DOI: 10.1038/bjc.2017.76.


Novel indolyl-chalcones target stathmin to induce cancer cell death.

Wegiel B, Wang Y, Li M, Jernigan F, Sun L Cell Cycle. 2016; 15(9):1288-94.

PMID: 26986925 PMC: 4889226. DOI: 10.1080/15384101.2016.1160980.


References
1.
Baldassarre G, Belletti B, Nicoloso M, Schiappacassi M, Vecchione A, Spessotto P . p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 2005; 7(1):51-63. DOI: 10.1016/j.ccr.2004.11.025. View

2.
Lin W, Chen S, Hu F, Chueh S, Pu Y, Yu H . Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology. 2009; 74(6):1264-9. DOI: 10.1016/j.urology.2009.04.088. View

3.
Brattsand G . Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer. 2000; 83(3):311-8. PMC: 2374559. DOI: 10.1054/bjoc.2000.1264. View

4.
Adams J, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-37. PMC: 2930981. DOI: 10.1038/sj.onc.1210220. View

5.
Rana S, Maples P, Senzer N, Nemunaitis J . Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008; 8(9):1461-70. DOI: 10.1586/14737140.8.9.1461. View